Values marked with an asterisk (*) differed significantly from the M1 reference value of zero liters (P < 0.05). Short dashed lines represent one-side SE bars. Prior to the evaluation of Selleck GSK2118436 osmolality and pH for the urine samples, both Control and Experimental groups were split into “”low”" and “”high”" subgroups using each group’s respective median values for daily PA, SRWC, and average PRAL. These subgroups were used as a basis for reevaluating the urine measures since each of these variables can independently influence urine osmolality and pH. Summary statistics for PA, SRWC, and average
PRAL for the resulting ACP-196 subgroups are provided in Table 5. A complete summary of urine osmolality results are provided in Tables 6 and 7 for Control and Experimental groups, respectively. There were no significant changes in urine osmolality for the Control group over the entire Testing Phase, regardless of whether the entire group or subgroups were evaluated. Urine osmolality for urine samples collected in the second week of the treatment
period for the Experimental group, however, were significantly higher than the pre-treatment reference value. The subgroup analyses also indicated that urine osmolality tended to be significantly higher at the end of the treatment period for Experimental subjects within the “”high”" daily PA, “”low”" SRWC, and “”high”" PRAL subgroups. Tables 8 and 9 show that the trends for changes in urine pH paralleled
those discussed for urine osmolality. Specifically, Decitabine there were NVP-LDE225 price no significant changes in urine pH across all measurements for the Control group which includes the daily PA, SRWC, and PRAL subgroup analyses (Table 8). In contrast, when considering the Experimental group urine measures (Table 9), pH increased progressively and significantly throughout the treatment period by approximately 0.3 to 0.8 units. This same trend was evident throughout the “”low”" and “”high”" Experimental subgroup analyses as well with the largest pH increases (+0.5 to +1.2 units) observed for the “”high”" daily PA, “”high”" SRWC, and “”high”" PRAL subgroups. Interestingly, observed changes in daily urine output, osmolality, and pH for the Experimental group all returned to pre-treatment levels during the post-treatment period. Table 5 Summary statistics of sub-group analysis variables reported as Mean ± SD (Range). Grouping Variables Control Group (n = 19) Experimental Group (n = 19) “”Low”" (n = 9) “”High”" (n = 10) “”Low”" (n = 9) “”High”" (n = 10) †Daily PA (mins/day) 41.2 ± 14.7 (15.0 – 63.0) 96.6 ± 19.9 (68.0 – 127.0) 51.3 ± SD (16.0 – 73.0) 102.7 ± 32.6 (75.0 – 173.0) ‡SRWC (L/day) 1.4 ± 0.3 (1.0 – 1.9) 3.1 ± 1.1 (2.0 – 5.6) 1.4 ± 0.23 (1.0 – 1.7) 2.95 ± 0.84 (1.8 – 4.7) §PRAL (mg/day) 5.72 ± 9.40 (-8.30 – 23.9) 45.30 ± 25.85 (24.60 – 114.90) 3.28 ± 11.8 (-22.2 – 15.0) 35.05 ± 17.3 (18.4 – 74.